Ann: Update on Oculopharyngeal Muscular Dystrophy Program, page-62

and you would have to wonder if Benitec was relying only on OPMD. That is simply not possible. The quarterly revealed half our spending was on proprietary programs so we can assume these were ready to be announced too.

Potentially, taking the best case scenario, we could get an announcement about promising OPMD progress (owned 100 %) and multiple exciting new programs using ddrnai. That would put a rocket under the share price because of the misunderstanding surrounding the present termination of the Axovant program.